RxDoctor Payments Data

David Allen, MD

Family Medicine · Holton, KSNPI 1952371163

Payments from drug & device makers

$3,742in general payments, 2019–2025

Across 237 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$578
  • AbbVie$491
  • Lilly USA, LLC$329
  • Novo Nordisk$274
  • Boehringer Ingelheim$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$164
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,72299%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,742 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$12,696
Medicare patients
66
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$56,647
JardianceEmpagliflozin63$54,738
OzempicSemaglutide46$52,383
TrulicityDulaglutide37$45,206
XareltoRivaroxaban41$41,302
EliquisApixaban46$40,808
MyrbetriqMirabegron57$31,644
JanuviaSitagliptin Phosphate21$22,191
Tresiba Flextouch U-200Insulin Degludec17$20,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,623
FarxigaDapagliflozin Propanediol16$13,561
Janumet XrSitagliptin Phos/Metformin Hcl20$13,094
Bydureon BciseExenatide Microspheres14$11,080
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,075
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$329$101,85388 claims
Boehringer IngelheimJardiance$173$54,73863 claims
Novo NordiskOzempic$274$52,38346 claims
Johnson & JohnsonXarelto, Invokana$112$47,71052 claims
PfizerEliquis, Premarin$93$42,87457 claims
MerckJanuvia, Janumet Xr$27$35,28541 claims
Astellas Pharma US IncMyrbetriq$54$31,64457 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$123$27,45654 claims
AstraZenecaFarxiga, Breztri Aerosphere$578$24,63633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Holton

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →